Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

Fig. 3

Sequential combination therapy with Cy/Lm-ANXA2 and PD-1 blockade improves survival and cure rate in a PDAC mouse model. a Schema of tumor implantation by the hemispleen procedure and treatment with Cy, Empty Lm or Lm-ANXA2, and anti-PD-1 antibody as indicated. b Kaplan Meier survival curves and (c) cure rate at day 120 of mice implanted with PDAC cells and treated with different combinations of Cy, Empty Lm, Lm-ANXA2, and the anti-PD-1 antibody. Untreated, (n = 8); Empty Lm/IgG, (n = 21); Empty Lm/anti-PD-1, (n = 22); Lm-ANXA2/IgG, (n = 19); Lm-ANXA2/anti-PD-1, (n = 18). Note that the results combined two independently repeated experiments and therefore have different numbers of mice in each treatment group

Back to article page